Pharma Capital

Advanced Oncotherapy secures additional £1.5mln loan; appoints new COO

The loan is repayable by next March, while Ed Lee is the new face among senior management
pound coins and pound notes
AVO now has £6.5mln financing agreements in place with Blackfinch

Shares in Advanced Oncotherapy PLC (LON:AVO) edged higher this morning after the proton therapy specialist secured a new £1.5mln, one-year loan with Blackfinch Investment.

This brings the total financing from Blackfinch to £6.5mln, following on from two prior agreements announced back in March and April of this year.

Unlike those two other arrangements, this loan is secured against known cash receivables and will be paid back once AVO receives those monies. The maximum loan term is one year, with the start backdated to 24 March 2017.

The loan carries an annual interest rate of 12%, and comes with 500,000 warrants which can be exercised at 100p each over the next five years.

Ed Lee appointed as new COO

Alongside the announcement of the new £1.5mln loan, AVO revealed it has appointed Ed Lee to the position of chief operating officer with immediate effect. He won’t be taking a seat board, however.

Lee joined the company earlier this year and will now be responsible for spearheading the operations and project management of AVO’s LIGHT proton therapy system.

He was previously the director of production and field service at Optivus Proton Therapy Inc and has worked across several heavily-regulated industries including with the aerospace and defence, nuclear and medical devices sectors.

“Ed's background gives him excellent insight into every step of the production and clinical-user processes for our LIGHT system,” said chief executive Nicolas Serandour.

He will be responsible for leading and driving the team to develop and produce the LIGHT system in an efficient and timely manner as demonstrated consistently in his previous roles.”

Shares nudged almost 5% higher to 16.5p.

View full AVO profile

Advanced Oncotherapy Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.